

CCC 2010

ACCREDITED SYMPOSIUM



CCRN

Canadian Cardiovascular Research Network

www.ccrnmd.com

CV QUEST 2010:

*A Glimpse into the Future...
The Next Decade*

CO-CHAIRS:

Milan Gupta, MD, FRCPC
Subodh Verma, MD, FRCSC

Sunday, October 24, 2010

9:30 a.m. – 10:00 a.m.
Breakfast and Registration

10:00 a.m. - 12:00 p.m.
Accredited Symposium

LOCATION:

Palais des congrès de Montréal
Room 517C

WHO SHOULD ATTEND: Cardiologists, surgeons, internal medicine specialists, endocrinologists, primary care physicians, fellows, residents, nurses interested in these disciplines.

LEARNING OBJECTIVES:

Throughout and following this session, the learner will be able to:

1. discuss the potential role of prevention of heart failure
2. evaluate the role of drugs and devices in the management of heart failure in the future
3. debate the role of primary prevention of risk factors versus intervention once risk factors are established
4. explore the potential for percutaneous valve technology as an alternative to open surgical intervention
5. discuss the potential role of personalized genetics to guide individualized risk stratification and drug selection

This session has been co-developed by the Canadian Cardiovascular Society and the Canadian Cardiovascular Research Network (CCRN).

PROGRAM OVERVIEW:

Four internationally recognized experts will share their forecasts on the practice of cardiovascular medicine in the year 2020. Despite recent advances, heart failure and CAD interventions remain challenged by unacceptably high morbidity and mortality. We will discuss the role of primary prevention, drugs and devices in the management of heart failure. Lifestyle and pharmacologic management will be considered as well as their effect on CAD prevention. Environmental and metabolic factors will be considered. Treatment for valvular heart disease remains challenging particularly when surgical intervention is required in patients with significant co-morbidities. The future of percutaneous valve replacement as an effective therapy for aortic valve disease will be compared with surgical valve replacement. Finally, pharmacogenomics is rapidly expanding, and the promise of tailored therapy has been with us for the past decade. Customized treatments that offer the most effective therapy with the least potential for toxicity will be discussed.



To register on-line for this symposium, please visit the CCRN website at www.ccrnmd.com

Co-Chairs:



Milan Gupta, MD, FRCPC

Associate Clinical Professor of Medicine,
McMaster University
Assistant Professor of Medicine,
University of Toronto
Division of Cardiology,
William Osler Health Centre,
Brampton, Ontario



Subodh Verma, MD, PhD, FRCSC, FAHA

Cardiac Surgeon
St-Michael's Hospital
Associate Professor
University of Toronto
Canada Research Chair in Atherosclerosis
Director, Traineeship in Atherosclerosis
Toronto, Ontario

With special guest: Charles R. Kerr, MD, FRCPC

President of the Canadian Cardiovascular Society; Professor, University of British Columbia;
Staff Cardiologist, Electrophysiologist, St. Paul's Hospital, Vancouver, BC

Faculty:



Clyde W. Yancy, MD, FACC, FAHA, MACP

President, American Heart Association, 2009-2010
Medical Director
Baylor Heart and Vascular Institute
Chief, Cardiothoracic Transplantation
Baylor University Medical Center
Dallas, Texas



John G. Webb, MD, FACC

McLeod Professor of Heart Valve Intervention,
University of British Columbia
Director of Cardiac Catheterization and
Interventional Cardiology Research,
St. Paul's Hospital
Vancouver, British Columbia



Robert M. Califf, MD

Duke Translational Medicine Institute
DTMI Director
Donald F. Fortin,
M.D. Professor of Cardiology,
School of Medicine,
Vice Chancellor for Clinical Research,
Durham, North Carolina



Robert Hegele, MD, FRCPC, FACP, FAHA, FCAHS

Jacob J. Wolfe Distinguished Medical Research Chair
Edith Schulich Vinet Canada Research Chair in Human
Genetics, Tier I
Martha G. Blackburn Chair in Cardiovascular Research
Director London Regional Genomics Centre
Scientist, Vascular Biology Research Group,
Robarts Research Institute
Distinguished University Professor, Departments of
Medicine (Division of Endocrinology) and Biochemistry,
University of Western Ontario
London, Ontario

AGENDA:

Opening Remarks

The Heart Failure Beast: Will we conquer it by 2020?

Intervention vs. Prevention. Will the landscape change by 2020?

An Obituary to Open Valve Replacement by 2020?

Pharmacogenomics: Will "smart" therapy come of age by 2020?

Discussion

Closing Remarks

10:00 a.m. - 12:00 p.m.

Dr. Milan Gupta and Dr. Charles Kerr

Dr. Clyde Yancy

Dr. Robert Califf

Dr. John Webb

Dr. Robert Hegele

All

Dr. Subodh Verma

For more information about this symposium and to register on-line, please visit the CCRN website at www.ccrnmd.com



THIS EVENT HAS BEEN MADE POSSIBLE THROUGH GRANT SUPPORT TO THE CANADIAN CARDIOVASCULAR RESEARCH NETWORK FROM THE FOLLOWING SPONSORS:

Li Ka Shing Knowledge Institute, Novartis Pharmaceuticals Canada Inc.,
Sanofi-aventis and Bristol-Myers Squibb (joint venture), Abbott, Merck Frosst, AstraZeneca Canada Inc.

This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. It is approved by the Canadian Cardiovascular Society for a maximum of 2 credits. This accredited symposium was co-developed with the Canadian Cardiovascular Society and the Canadian Cardiovascular Research Network and was planned to ensure the evidence presented is valid, objective and balanced.

Through an agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Canadian Cardiovascular Society designated this live educational activity for a maximum of 2 AMA PRA category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.



Canadian Cardiovascular Society

Leadership. Knowledge. Community.

for a maximum of 2 hours of Section 1 credits.